CA-POINT2WEB
31.7.2024 18:54:28 CEST | Business Wire | Press release
Point2Web, your ultimate marketing powerhouse in creative, advertising, and performance marketing, is thrilled to announce its appointment as the first Agency Sales Partner in Europe for NewsBreak, America's leading platform for local news and information, with over 40 million monthly active users.
Together, Point2Web and NewsBreak are poised to deliver exceptional advertising solutions that deeply engage local audiences. This partnership aims to drive significant growth and performance for Point2Web clients by combining the strengths of both companies to create something truly groundbreaking. The collaboration is expected to foster innovation, enhance service excellence, and achieve positive results for NewsBreak’s local users and their communities across America.
By utilizing NewsBreak's innovative technology and unrivaled local footprint, brands can revolutionize their local and targeted advertising and help direct resources where they are needed most. Point2Web's industry-leading expertise will further enable clients to amplify their advertising impact on an unprecedented scale. The collaboration will be particularly beneficial to advertisers in insurance, finance, travel, home improvement, e-commerce, and casual gaming, among others.
Partnership Highlights:
- Extended Reach: Point2Web clients will now have access to NewsBreak's 40 million users across the U.S., significantly enhancing the impact of their advertising campaigns. This access ensures advertisers can reach a vast yet highly engaged user base.
- Innovative Solutions: The partnership brings NewsBreak's use of new technology to Point2Web's clientele.
- Global Expertise, Local Impact: Point2Web's global presence and deep expertise in performance networks, combined with NewsBreak's robust local information platform, ensures a targeted and effective advertising strategy that will resonate with local communities. This synergy enables advertisers to craft messages that are both globally informed and locally relevant.
- Fostering Innovation and Achieving Success: Both Point2Web and NewsBreak share a strong commitment to innovation, excellence in service, and achieving positive results for their stakeholders. This partnership is a testament to their joint vision of pushing the boundaries of what is possible in digital advertising.
“Through our partnership with NewsBreak, we’re not just expanding the digital footprint of our clients; we’re providing them with the tools and platforms necessary to achieve unprecedented levels of engagement and success in their advertising campaigns,” said Valentine Kovalenko, COO at Point2Web. “This collaboration is a testament to our unwavering commitment to innovation and excellence in service. NewsBreak’s audience is highly engaged and of high quality, which ensures that our clients' ads reach a valuable and responsive demographic.”
“We are thrilled to partner with Point2Web, whose global expertise and innovative approach align perfectly with our mission to create a local media ecosystem where information is readily available and easily accessible," said Ryan Ludlow, General Manager of NewsBreak Advertising. "By leveraging our cutting-edge new technology and working with strategic partners like Point2Web, we remain dedicated to enhancing advertiser success and maintaining our focus on ad quality.”
For more information about this partnership and how it can benefit your advertising strategies, please visit our website.
About Point2Web
Point2Web is a global advertising agency that specializes in performance marketing and exceptional creative development. We unite media buying, creative development, and agency access to top-tier ad platforms to provide a powerful blend of services, expertise, and exclusive partnerships around the globe.
Our dedication to excellence and innovation is evident in every project we undertake. Our brand is anchored by our core values: reliability, mutual trust, top-tier service, steadfast commitment, and unending innovation. As we expand our horizons, Point2Web is committed to transparency, integrity, and achieving superior results for our clients.
We redefine the standard with our forward-thinking mindset and the latest in technology, setting new benchmarks in creativity. With a footprint in nine countries, advertisers and publishers worldwide can benefit from our unwavering commitment to driving their growth.
About NewsBreak
NewsBreak is the leading platform for local news and information in the United States, providing users with the local news and information they want and need in a digital form. By using cutting-edge technology that learns users’ preferences to curate tailored content for them, NewsBreak gathers community-focused news and information from over 10,000 sources in a timely, accessible, and easy-to-use way at no cost to users. NewsBreak is bridging the gap between new technology and traditional local media, offering an innovative digital solution that benefits everyone, from individual users and their communities to businesses across America.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729481955/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom